Legend Biotech Corporation closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech's existing autologous CAR-T cell therapy candidate, LB2102 (NCT05680922). Under the terms of the license agreement closed on January 3, 2024, Legend Biotech will receive a $100 million upfront cash payment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.3 USD | +0.85% |
|
+4.54% | -23.05% |
07-04 | Genscript Biotech's Phase 3 Multiple Myeloma Drug Trial Yields Positive Results | MT |
07-02 | Legend Biotech Says Myeloma Drug Shows Positive Overall Survival Results | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.05% | 8.44B | |
+16.61% | 122B | |
+17.75% | 112B | |
+18.22% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.6B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Legend Biotech Corporation Announces Closing of License Transaction for Certain Car-T Therapies Targeting DLL3 with Novartis Pharma AG